Acute liver failure inhibitor and its efficacy evaluation method

Japanese Patent JP6296366

B2

The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

Hirohito Tsubouchi
Akio Ido
Tsutomu Chiba
Akira Shimizu

JP2016078387A

March 20, 2018

April 08, 2016

Click for automatic bibliography generation  

Kyoto University

G01N33/68; A61K38/22; A61P1/16; G01N33/53

JP10167982A
JP3086835A

井戸 章雄 他,組換えヒト肝細胞増殖因子を投与した劇症肝炎、遅発性肝不全の4例,日本腹部救急医学会雑誌,2009年,Vol.29, No.4,pp.609-611
井戸 章雄 他,肝再生を目的とした肝細胞増殖因子(HGF)を用いた新規治療法の開発,日本消化器病学会雑誌,2004年,Vol.101 臨時増刊号大会,p.A422
SHIOTA, G. et al.,Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant,Res. Commun. Mol. Pathol. Pharmacol.,1998年,Vol.101, No.1,pp.3-12

Takashima Ichi
Kyoko Doi
Mitsunori Kamata
Yaeko Tamura
Murata Miyuki
Junzo Koike
Hirofumi Toma

Previous Patent: The camera control unit for operation endoscopes

Next Patent: MONITORING METHOD FOR POWER SUPPLY